D
David E. Kleiner
Researcher at National Institutes of Health
Publications - 560
Citations - 60934
David E. Kleiner is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Liver biopsy & Medicine. The author has an hindex of 104, co-authored 495 publications receiving 50296 citations. Previous affiliations of David E. Kleiner include University of Virginia & Tufts University.
Papers
More filters
Journal ArticleDOI
Presentation and outcomes with clinically apparent interferon beta hepatotoxicity.
Robert J. Fontana,Paul H. Hayashi,Herbert L. Bonkovsky,Herbert L. Bonkovsky,David E. Kleiner,Sweta Kochhar,Jiezhun Gu,Marwan Ghabril +7 more
TL;DR: Interferon beta hepatotoxicity occurs mostly in women and has a variable, but often prolonged time to onset, and autoimmune features suggestive of an immunologic basis to this adverse drug reaction are demonstrated.
Journal ArticleDOI
Expression in transgenic mice of dominant interfering Fas mutations: a model for human autoimmune lymphoproliferative syndrome.
Youngnim Choi,Venktesh R. Ramnath,Ashlyn Eaton,Amy Chen,Karen L. Simon-Stoos,David E. Kleiner,Jan Erikson,Jennifer M. Puck +7 more
TL;DR: In this article, the influence of genetic background on phenotype was studied by comparing transgenic mice on FVB/N and (FVB/n x MRL) backgrounds with syngenetic control mice and with MRL and MRL lpr/lpr mice.
Journal ArticleDOI
Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B.
Marc G. Ghany,Jordan J. Feld,Xiongce Zhao,Theo Heller,E. Doo,Yaron Rotman,P. Nagabhyru,Christopher Koh,David E. Kleiner,Elizabeth C. Wright,T. J. Liang,Jay H. Hoofnagle +11 more
TL;DR: Combination antiviral therapy holds the promise of increasing response rates while decreasing antiviral resistance, but has yet to be shown to be beneficial or necessary in chronic hepatitis B.
Journal ArticleDOI
Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial.
Kathleen E. Corey,Laura A. Wilson,Akif Altinbas,Katherine P. Yates,David E. Kleiner,Raymond T. Chung,Ronald M. Krauss,Naga Chalasani +7 more
TL;DR: Dyslipidaemia is frequent in non‐alcoholic steatohepatitis (NASH); however, it is unclear if improvement in liver histology is associated with favourable changes in cardiovascular disease (CVD) risk.
Journal ArticleDOI
Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Co-infected Adults.
Richard K. Sterling,Wendy C. King,Abdus S. Wahed,David E. Kleiner,Mandana Khalili,Mark S. Sulkowski,Raymond T. Chung,Mamta K. Jain,Mauricio Lisker-Melman,David Wong,Marc G. Ghany +10 more
TL;DR: VCTE is a better biomarker of advanced fibrosis compared with APRI or FIB‐4 in HBV/HIV co‐infected adults on combined antiretroviral therapy using VCTE dual cutoffs, and approximately two‐thirds of patients could avoid biopsy to determineAdvanced fibrosis.